UNSPSC 51283506: Cloxacillin benzathine

This classification denotes a penicillin antibiotic with the molecular formula 2C19H18ClN3O5S.C16H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AC79L7PV2G, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2.alpha.,5.alpha.,6.beta.))-, compd. with n,n'-bis(phenylmethyl)-1,2-ethanediamine (2:1), but more generally known as cloxacillin benzathine, which bears US NIH Compound Identifier 64706.

UNSPSC 51283506 Cloxacillin benzathine is a Commodity code that nominally describes a specific penicillin antibiotic, but recent state and local procurement activity under this code shows little direct alignment with the code's product name. The two most recent opportunities posted under this code involve pharmaceutical supply through piggyback contracts and direct procurement of naloxone and drug deactivation systems — neither of which is cloxacillin benzathine. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline hyclate and ciprofloxacin hydrochloride tablets over a 12-month initial term with two optional renewal years. Seminole County, Florida issued an IFB in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. State and local buyers using this code appear to be health departments and county health and safety agencies, though the code's recent activity does not reflect consistent procurement of the product nominally named.

Activity under this code is minimal and geographically scattered. Recent opportunities are isolated to Illinois and Florida, with no pattern of repeat activity or concentration. The Illinois procurement was a completed award through a cooperative purchasing vehicle rather than an open solicitation, and the Florida opportunity carried a response deadline of July 26, 2023, making it historical rather than current. The code shows little indication of active or predictable state and local procurement aligned with its nominal scope, suggesting either inconsistent tagging of pharmaceutical purchases or limited current demand for cloxacillin benzathine specifically among state and local health systems.